Two recent studies focus on radiographic progression in ankylosing spondylitis and the risk of osteoporosis in axial spondyloarthritis.
References1. Gensler LS, Gianfrancesco M, Weisman MH, et al. Combined effects of tumour necrosis factor inhibitors and NSAIDs on radiographic progression in ankylosing spondylitis. Presented at: EULAR 2018; June 13-16, 2018; Amsterdam, The Netherlands. Abstract OP0198.2. Fitzgerald G, Anachebe T, O’ Shea F. Low bone mineral density is common in axial spondyloarthropathy. Presented at: EULAR 2018; June 13-16, 2018; Amsterdam, The Netherlands. Abstract THU0255.
Two studies presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, The Netherlands, focus on radiographic progression in ankylosing spondylitis and the risk of osteoporosis in axial spondyloarthritis.
Gensler and colleagues from multiple US centers found that the combination of NSAIDs and tumor necrosis factor inhibitor (TNFi) drugs had the greatest effect on slowing the radiographic progression of ankylosing spondylitis (AS).1 Fitzgerald and fellow researchers in Ireland discovered that low bone mineral density (BMD) is more common than previously thought in patients with axial spondyloarthritis (axSpA).2
Thumb through the slides for the details of the studies and the take-home points for physicians.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score–C-Reactive Protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; DXA, dual-energy X-ray absorptiometry; OR, odds ratio.
The mean (SD) ASDAS-CRP was 2.3 (1), BASDAI was 3.9 (2.2), BASMI was 4.3 (1.9), and BASFI was 3.8 (2.5), which reflect mild to moderate disease burden.
Low BMD was most prevalent at the spine, with 44% of the cohort affected, followed by the femoral neck (30.1%, n = 22).